REGENXBIO Inc. (Nasdaq: RGNX) today announced a program update from its ongoing clinical investigation of RGX-314 for the treatment of wet AMD, a leading cause of vision loss globally.
Top Biotech Companies Hiring in Maryland: Summer 2022 Edition
Published on :Here’s our Summer 2022 Roundup of top Maryland life sciences companies with more than 10 active job listings across a wide range of fields and experience levels.
REGENXBIO President and CEO Ken Kills Named an EY Entrepreneur Of The Year 2022 Mid-Atlantic Award Winner
Published on :REGENXBIO President and CEO Ken Kills Named an EY Entrepreneur Of The Year 2022 Mid-Atlantic Award Winner Congratulations to our region’s Entrepreneur Of The Year® winners, who were selected by [….]
REGENXBIO on Why It’s Better Here
Published on :For Curran Simpson, Chief Operations and Technology Officer at REGENXBIO, Maryland has the “ideal mix” of talent for process development and manufacturing. Because if that, it was a no-brainer for the company to opening of its new Manufacturing Innovation Center gene therapy manufacturing facility in Rockville.
The new 132,000 square-foot-facility was designed to boost manufacturing of the company’s NAV Technology-based adeno-associated virus (AAV) vectors at scales up to 2,000 liters. REGENXBIO’s AAV vector platform has been licensed to other companies and was used in the development of Novartis’ Zolgensma, a gene therapy for spinal muscular atrophy. With its new site that includes two independent bulk drug substance production suites, a final drug product suite and integrated quality control labs, REGENXBIO is one of only a few gene therapy companies worldwide with a GMP facility capable of production at scales up to 2,000 liters.
REGENXBIO Opens State-of-the-Art Gene Therapy Manufacturing Facility
Published on :REGENXBIO Inc. (Nasdaq: RGNX) today is celebrating the opening of its new Manufacturing Innovation Center gene therapy manufacturing facility.
Cartesian, BD and REGENXBIO’s Ken Mills Take Home Top Honors at MTC’s Industry Awards Celebration
Published on :The Maryland Tech Council, the largest technology and life science trade association in the state, announced the winners of its 2022 Industry Awards Thursday at the Bethesda North Marriott Hotel & Conference Center. The event, which honored companies, executives, students, and educators in 15 categories, marked the first in-person gathering for the Industry Awards Celebration since 2019.
REGENXBIO Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights
Published on :REGENXBIO Inc. (Nasdaq: RGNX) today announced financial results for the fourth quarter ended December 31, 2021, and recent operational highlights.
The Promise of Gene Therapy Offers More Hope for Rare Disease Cures in 2022
Published on :While the field of gene therapy is still relatively new, it’s moving at a breakneck pace. In fact, 1,745 gene therapies are currently in development around the world! Technological advancements in gene editing, modulation, and replacement technologies have helped to advance this new breed of therapies, raising hope for cures for many of these rare diseases in the near future.
REGENXBIO Presents Positive Initial Data from Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I at 18th Annual WORLDSymposium™ 2022
Published on :REGENXBIO Inc. (Nasdaq: RGNX) today announced positive interim data are being presented at the 18th Annual WORLDSymposium™ from five patients in the ongoing Phase I/II trial and one patient from a single-patient Investigational New Drug (IND) application of RGX-111 for the treatment of severe Mucopolysaccharidosis Type I (MPS I).
REGENXBIO Starts 2022 by Moving DMD Gene Therapy into the Clinic and Advancing AbbVie Partnership
Published on :Rare disease-focused REGENXBIO hit the ground running in 2022 with its developmental programs for Duchenne Muscular Dystrophy and wet age-related macular degeneration. The Maryland-based company received clearance from the U.S. Food and Drug Administration to initiate a first-in-human study of its gene therapy for the rare form of muscular dystrophy.